FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123407263> ?p ?o ?g. }

• W2123407263 abstract "MET is a receptor tyrosine kinase that is activated by the ligand HGF and this pathway promotes cell survival, migration, and motility. In accordance with its oncogenic role, MET is constitutively active, mutated, or over-expressed in many cancers. Corollary to its impact, inhibition of MET kinase activity causes reduction of the downstream signaling and demise of cells. In myeloma, a B-cell plasma malignancy, MET is neither mutated nor over-expressed, however, HGF is increased in plasma or serum obtained from myeloma patients and this was associated with poor prognosis. The small-molecule, amuvatinib, inhibits MET receptor tyrosine kinase. Based on this background, we hypothesized that targeting the HGF/MET signaling pathway is a rational approach to myeloma therapy and that myeloma cells would be sensitive to amuvatinib. Expression of MET and HGF mRNAs in normal versus malignant plasma cells was compared during disease progression. Cell death and growth as well as MET signaling pathway were assessed in amuvatinib treated primary myeloma cells and cell lines. There was a progressive increase in the transcript levels of HGF (but not MET) from normal plasma cells to refractory malignant plasma cells. Amuvatinib readily inhibited MET phosphorylation in primary CD138+ cells from myeloma patients and in concordance, increased cell death. A 48-hr amuvatinib treatment in high HGF-expressing myeloma cell line, U266, resulted in growth inhibition. Levels of cytotoxicity were time-dependent; at 24, 48, and 72 h, amuvatinib (25 μM) resulted in 28%, 40%, and 55% cell death. Consistent with these data, there was an amuvatinib-mediated decrease in MET phosphorylation in the cell line. Amuvatinib at concentrations of 5, 10, or 25 μM readily inhibited HGF-dependent MET, AKT, ERK and GSK-3-beta phosphorylation. MET-mediated effects were not observed in myeloma cell line that has low MET and/or HGF expression. These data suggest that at the cellular level MET/HGF pathway inclines with myeloma disease progression. Amuvatinib, a small molecule MET kinase inhibitor, is effective in inducing growth inhibition and cell death in myeloma cell lines as well as primary malignant plasma cells. These cytostatic and cytotoxic effects were associated with an impact on MET/HGF pathway." @default.
• W2123407263 created "2016-06-24" @default.
• W2123407263 creator A5009968872 @default.
• W2123407263 creator A5018689852 @default.
• W2123407263 creator A5020548821 @default.
• W2123407263 creator A5024454882 @default.
• W2123407263 creator A5033504238 @default.
• W2123407263 creator A5036944657 @default.
• W2123407263 creator A5043830614 @default.
• W2123407263 creator A5059186901 @default.
• W2123407263 creator A5062057879 @default.
• W2123407263 creator A5074654320 @default.
• W2123407263 creator A5088930582 @default.
• W2123407263 date "2013-12-01" @default.
• W2123407263 modified "2023-10-15" @default.
• W2123407263 title "Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines" @default.
• W2123407263 cites W1572876072 @default.
• W2123407263 cites W1607745684 @default.
• W2123407263 cites W1777794242 @default.
• W2123407263 cites W18131798 @default.
• W2123407263 cites W1896782101 @default.
• W2123407263 cites W1911676479 @default.
• W2123407263 cites W1965570423 @default.
• W2123407263 cites W1969705003 @default.
• W2123407263 cites W1976841593 @default.
• W2123407263 cites W1982261178 @default.
• W2123407263 cites W1989750981 @default.
• W2123407263 cites W1991753648 @default.
• W2123407263 cites W1994921020 @default.
• W2123407263 cites W2006143091 @default.
• W2123407263 cites W2009169267 @default.
• W2123407263 cites W2012169430 @default.
• W2123407263 cites W2013187395 @default.
• W2123407263 cites W2017436400 @default.
• W2123407263 cites W2018890642 @default.
• W2123407263 cites W2025924761 @default.
• W2123407263 cites W2026023049 @default.
• W2123407263 cites W2028330103 @default.
• W2123407263 cites W2032733162 @default.
• W2123407263 cites W2034029588 @default.
• W2123407263 cites W2036108923 @default.
• W2123407263 cites W2045691095 @default.
• W2123407263 cites W2053964791 @default.
• W2123407263 cites W2069551399 @default.
• W2123407263 cites W2084913318 @default.
• W2123407263 cites W2087861588 @default.
• W2123407263 cites W2091022495 @default.
• W2123407263 cites W2092324321 @default.
• W2123407263 cites W2100319157 @default.
• W2123407263 cites W2101476607 @default.
• W2123407263 cites W2108568329 @default.
• W2123407263 cites W2113011422 @default.
• W2123407263 cites W2118310862 @default.
• W2123407263 cites W2120316083 @default.
• W2123407263 cites W2120795894 @default.
• W2123407263 cites W2137998437 @default.
• W2123407263 cites W2139073495 @default.
• W2123407263 cites W2140126391 @default.
• W2123407263 cites W2146012957 @default.
• W2123407263 cites W2149808918 @default.
• W2123407263 cites W2150832644 @default.
• W2123407263 cites W2157423336 @default.
• W2123407263 cites W2165970948 @default.
• W2123407263 cites W2169611936 @default.
• W2123407263 cites W295899822 @default.
• W2123407263 cites W2999700545 @default.
• W2123407263 cites W4211135634 @default.
• W2123407263 cites W8998063 @default.
• W2123407263 doi "https://doi.org/10.1186/1756-8722-6-92" @default.
• W2123407263 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5064904" @default.
• W2123407263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27737688" @default.
• W2123407263 hasPublicationYear "2013" @default.
• W2123407263 type Work @default.
• W2123407263 sameAs 2123407263 @default.
• W2123407263 citedByCount "22" @default.
• W2123407263 countsByYear W21234072632014 @default.
• W2123407263 countsByYear W21234072632015 @default.
• W2123407263 countsByYear W21234072632016 @default.
• W2123407263 countsByYear W21234072632017 @default.
• W2123407263 countsByYear W21234072632018 @default.
• W2123407263 countsByYear W21234072632019 @default.
• W2123407263 countsByYear W21234072632020 @default.
• W2123407263 countsByYear W21234072632022 @default.
• W2123407263 countsByYear W21234072632023 @default.
• W2123407263 crossrefType "journal-article" @default.
• W2123407263 hasAuthorship W2123407263A5009968872 @default.
• W2123407263 hasAuthorship W2123407263A5018689852 @default.
• W2123407263 hasAuthorship W2123407263A5020548821 @default.
• W2123407263 hasAuthorship W2123407263A5024454882 @default.
• W2123407263 hasAuthorship W2123407263A5033504238 @default.
• W2123407263 hasAuthorship W2123407263A5036944657 @default.
• W2123407263 hasAuthorship W2123407263A5043830614 @default.
• W2123407263 hasAuthorship W2123407263A5059186901 @default.
• W2123407263 hasAuthorship W2123407263A5062057879 @default.
• W2123407263 hasAuthorship W2123407263A5074654320 @default.
• W2123407263 hasAuthorship W2123407263A5088930582 @default.
• W2123407263 hasBestOaLocation W21234072631 @default.
• W2123407263 hasConcept C126322002 @default.
• W2123407263 hasConcept C170493617 @default.
• W2123407263 hasConcept C190283241 @default.

• next